Exact Sciences, Healthmine Partner to Boost Cologuard Screening Rates via Health Plan Incentives
Exact Sciences Corporation (NASDAQ:EXAS) is one of the most promising long-term stocks to buy.
Exact Sciences Corp (EXAS)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 966,271 | $52,864,686 | -6% | 1.03% |
| 2. | RWC Asset Management Tord Stallvik (Ceo) | 6,352 | $347,518 | 0.02% | |
| 3. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.35 | 19,500 | $1,001,325.00 | 1,074,191 | 2024-11-13 | Filing | |
| $37.71 | 2,500 | $94,275.00 | 60,858 | 2017-08-17 | Filing | |
| $13.84 | 10,000 | $138,400.00 | 136,379 | 2016-12-14 | Filing | |
| $18.10 | 5,000 | $90,500.00 | 121,247 | 2016-09-01 | Filing | |
| $17.93 | 3,380 | $60,613.20 | 105,927 | 2016-08-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $65.00 | 12,000 | $780,000.00 | 60,759 | 2025-10-24 | Filing | |
| $60.00 | 1,500 | $90,000.00 | 14,085 | 2025-10-09 | Filing | |
| $60.00 | 2,000 | $120,000.00 | 57,962 | 2025-10-09 | Filing | |
| $42.02 | 1,485 | $62,399.70 | 59,962 | 2025-08-13 | Filing | |
| $53.20 | 3,207 | $170,612.40 | 72,759 | 2025-06-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,909,501 | $213,888,799 | 0.07% | |
| 2. | 1,286,595 | $70,389,612 | 0.04% | |
| 3. | 54,415,000 | $52,347,230 | 0.05% | |
| 4. | 892,989 | $48,855,428 | 1.47% | |
| 5. | 791,527 | $43,304,442 | 0.56% |
News See All
12 Most Promising Long-Term Stocks to Buy
On September 12, Abby Joseph Cohen, Columbia Business School professor and former Goldman Sachs partner & chief US strategist, joined 'Squawk Box' on CNBC to discuss the latest market trends, state of...
Jefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS)
Exact Sciences Corporation (NASDAQ:EXAS) is one of the best strong buy growth stocks to buy now.
10 Best Strong Buy Growth Stocks to Buy Now
On August 27, Komal Sri-Kumar, Sri-Kumar Global Strategies president, appeared on CNBC’s ‘Squawk Box’ to talk about the fallout from President Trump’s firing of Fed Governor Lisa Cook, the effects...
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jeannie, and I will be your conference operator today.
Will Exact Sciences Corporation (EXAS) Continue to Penetrate the Market with Its Cologuard Test?
Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Exact Sciences' Oncodetect MRD Test Gains Medicare Coverage for Colorectal Cancer
Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Concerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting Growth
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap.
Exact Sciences Corporation (NASDAQ:EXAS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
Hedge Fund Resource Center Billionaire Hedge Funds
